Cat. No. 1124
Chemical Name: (R)-1,4-Dihydro-2,6-dimethyl-4-(3-n
Biological ActivityL-type Ca2+ channel blocker and α1A-adrenoceptor antagonist; less active enantiomer. (S)-(+)-Niguldipine hydrochloride (Cat. No. 1123) also available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Wetzel et al (1995) Discovery of alpha1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J.Med.Chem. 38 1579. PMID: 7752182.
Hollt et al (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem.Pharmacol. 43 2601. PMID: 1352973.
Boer et al (1989) (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha1-adrenoceptor. Eur.J.Pharmacol. 172 131. PMID: 2548881.
Graziadei et al (1989) Stereoselective binding of niguldipine enantiomers to alpha1A-adrenoceptors labeled with [3H]5-methyl-urapidil. Eur.J.Pharmacol. 172 329. PMID: 2555206.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses (R)-(-)-Niguldipine hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (R)-(-)-Niguldipine hydrochloride, supplier, Ca2+, channel, blocker, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenoceptor, a1-adrenergic, α1-adrenergic, alpha1-adrenergic, Receptors, Calcium, CaV, Channels, L-Type, voltage-gated, voltage-dependent, Tocris Bioscience, Adrenergic α1 Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Selective, high affinity, non-competitive α1A adrenoceptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.